Skip to main content
Trials logoLink to Trials
. 2023 Jul 31;24:487. doi: 10.1186/s13063-023-07546-z

Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

Wei Bai 1,#, Fan Yang 1,#, Huji Xu 2, Wei Wei 3, Hongbin Li 4, Liyun Zhang 5, Yi Zhao 6, Xiaofei Shi 7, Yan Zhang 8, Xiaofeng Zeng 1,, Xiaomei Leng 1,
PMCID: PMC10388526  PMID: 37525264

Correction: BMC Trials 24, 112 (2023)

https://doi.org/10.1186/s13063-023-07087-5

Following publication of the original article [1], we have been notified that affiliations 1 to 4 are actually different titles within the same department and should be gathered under just one affiliation.

Additionally, the following sentence was added in the Funding section: This study was supported by the National High Level Hospital Clinical Research Funding (2022-PUMCH-A-227).

The original article has been corrected.

Footnotes

Wei Bai and Fan Yang contributed equally to this study.

Contributor Information

Xiaofeng Zeng, Email: xiaofeng.zeng@cstar.org.cn.

Xiaomei Leng, Email: lpumch@126.com.

Reference

  • 1.Bai, et al. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients. BMC Trials. 2023;24:112. doi: 10.1186/s13063-023-07087-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Trials are provided here courtesy of BMC

RESOURCES